Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

NCT05255523 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: pyrotinib

Sponsor

Fujian Medical University Union Hospital